Q-Med AB: Year-End Report 2009

(Thomson Reuters ONE) - January - December * Group revenues from sales of goods and royalties amounted to 1,364 (1,272) MSEK. * Earnings per share amounted to 6.89 (0.34) SEK. * Operating income amounted to 738 (50) MSEK. * In April 2009 Q-Med AB and Oceana Therapeutics, based in the US, entered into global agreements regarding commercialization rights to Deflux® and Solesta(TM). The agreements gave Q-Med an initial payment of 517 MSEK in total in June, partly as a purchase sum for Q-Med Scandinavia, Inc., the subsidiary that was divested within the framework of the agreements, and partly as payment for Oceana Therapeutics' share of certain study costs. Further revenues from the product development collaboration with Oceana Therapeutics were subsequently received during the fourth quarter and in total a net revenue of 505 MSEK has been recorded for the whole year in the Group income statement in the Other operating revenues row. * Revenues within the Esthetics product area amounted to 1,152 (1,037) MSEK and operating income was 252 (172) MSEK. For the Hospital Healthcare product area revenues from sales of goods and royalties were 212 (235) MSEK and operating income was 554 (-19) MSEK. Operating income includes the net revenue from the Oceana deal. * Net income after tax amounted to 685 (33) MSEK.October - December * Group revenues from sales of goods and royalties amounted to 348 (336) MSEK during the fourth quarter and operating income amounted to 62 (-50) MSEK. Operating income for the Esthetics product area amounted to 57 (-5) MSEK and for the Hospital Healthcare product area operating income amounted to 17 (3) MSEK. * Net income after tax amounted to 51 (-44) MSEK during the fourth quarter. * On December 7 Q-Med AB and Oceana Therapetutics announced that the Solesta(TM) study for the treatment of patients with fecal incontinence, which will be used for registration of the product in the USA, had achieved both of its main objectives. Q-Med and Oceana Therapeutics intend to submit a premarket approval (PMA) application based on the results of the study to the FDA (US Food and Drug Administration) during the first quarter of 2010.Events after the end of the period * Medicis, Q-Med's partner in North America, announced on February 3 that Restylane® with lidocaine (Restylane®-L) and Restylane Perlane(TM) with lidocaine (Perlane®-L) had been approved in the USA. * Q-Med has given notice to approximately 30 co-workers at the Uppsala facility as part of the company's work on changing the competence in the business and making it more effective. * The Board intends to propose to the Annual General Meeting a dividend of 1.50 SEK per share.Queries should be addressed to:Bengt ?erup, President and CEOTel: +46 70 974 9025Alexander Kotsinas, Vice President and CFOTel: +46 73 500 1111Future financial reports and calendar: Interim report January - March 2010 April 23, 2010 Annual General Meeting April 28, 2010 Interim report January - June 2010 July 22, 2010 Interim report January - September 2010 October 22, 2010Election committee:Robert Wikholm,robert.wikholm(at)vinge.se ,ChairmanLars Bergkvist, Lannebo FonderAnders MiltonKerstin Stenberg, Robur FonderBengt ?erupFebruary 12, 2010UppsalaQ-Med AB (publ.)Bengt ?erupPresident and CEOThe information in this report is such as that which Q-Med is required todisclose in accordance with the Swedish Securities Market Act and/or theFinancial Instruments Trading Act. The information was submitted for disclosureat 7.30 a.m. on February 12, 2010.Q-Med AB is a medical device company. The company develops, manufactures,markets, and sells primarily medical implants. The majority of the products arebased on the company's patented technology, NASHA(TM), for the production ofstabilized non-animal hyaluronic acid. The product portfolio today contains:Restylane® for filling lines and folds, contouring and creating volume in theface, Macrolane(TM) for body contouring, Durolane(TM) for the treatment ofosteoarthritis of the hip and knee joints, Deflux® for the treatment ofvesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,and Solesta(TM) for the treatment of fecal incontinence. Sales are made throughthe company's own subsidiaries or distributors in over 70 countries. Q?Med todayhas about 650 coworkers, with approximately 400 at the company's head office andproduction facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Capsegment of the NASDAQ OMX Nordic.Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporateidentity number 556258-6882.Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info(at)q-med.com. Web: www.q-med.com .The full report with tables can be downloaded from the following link.[HUG#1383837] Q4 2009: http://hugin.info/130306/R/1383837/342692.pdf

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Leseranfragen:
PresseKontakt / Agentur:
Bereitgestellt von Benutzer: hugin
Datum: 12.02.2010 - 02:32 Uhr
Sprache: Deutsch
News-ID 1010326
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

Uppsala

Phone:

Kategorie:

Business News

Anmerkungen:


Diese Pressemitteilung wurde bisher 99 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Q-Med AB: Year-End Report 2009
"
steht unter der journalistisch-redaktionellen Verantwortung von

Q-Med AB (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Alle Meldungen von Q-Med AB